Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) Income towards Parent Company (2016 - 2026)

Tenax Therapeutics' Income towards Parent Company history spans 7 years, with the latest figure at -$17.0 million for Q4 2017.

  • On a quarterly basis, Income towards Parent Company rose 74.78% to -$17.0 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$9.2 million, a 85.63% increase, with the full-year FY2025 number at -$52.6 million, down 198.62% from a year prior.
  • Income towards Parent Company hit -$17.0 million in Q4 2017 for Tenax Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for TENX hit a ceiling of $4.7 million in Q2 2016 and a floor of -$67.5 million in Q4 2016.
  • Historically, Income towards Parent Company has averaged -$7.4 million across 4 years, with a median of -$2.4 million in 2013.
  • The widest YoY moves for Income towards Parent Company: up 244.99% in 2016, down 547.62% in 2016.
  • Tracing TENX's Income towards Parent Company over 4 years: stood at -$1.9 million in 2013, then crashed by 459.84% to -$10.4 million in 2015, then tumbled by 547.62% to -$67.5 million in 2016, then soared by 74.78% to -$17.0 million in 2017.
  • Business Quant data shows Income towards Parent Company for TENX at -$17.0 million in Q4 2017, $1.3 million in Q3 2017, and $3.0 million in Q2 2017.